Compare AstraZeneca plc (AZN) vs Eni SpA (E) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Eni SpA — how do they compare? AstraZeneca plc trades at $159.33 (market cap $250.84B), while Eni SpA trades at $55.28 (market cap $78.80B). The key difference: AstraZeneca plc is far larger — about 3.2× Eni SpA's market cap, and Eni SpA pays the higher dividend (4.45%). Which is the better fit depends on your goals.
| AZN | E | |
|---|---|---|
Market Cap | $250.84B | $78.80B |
Sector | Health | Energy |
52-Week High | $209.48 | $57.61 |
52-Week Low | $147.06 | $34.03 |
Enterprise Value | $278.12B | $104.11B |
Dividend Yield | 1.97% | 4.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.42, up 0.22% today, amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth to $58.74B in 2025 and net income of $10.23B, supported by a P/E of 24.16 and robust profitability margins. Recent news highlights potential talks with Bristol Myers Squibb, though a senior source denied ongoing discussions (Reuters, 2026-08-05).
The outlook is mixed: solid earnings beats and a 47.5% analyst buy rating support upside, but technical weakness and merger uncertainty pose near-term risks. Long-term growth hinges on execution amid competitive and regulatory pressures, with the stock offering value if merger rumors subside and fundamentals prevail.
Eni (E) trades at $53.61, down 1.22% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. Recent Q2 2026 earnings missed estimates despite 21.5% revenue growth, while the company increased its share buyback program. Valuation ratios appear attractive with a P/E of 12.08 and P/S of 0.79. Cash flow from operations remains strong at $13.33 billion for 2025, supporting dividend payments and strategic investments.
The outlook for Eni is cautiously optimistic, driven by production growth and strategic partnerships, but faces risks from commodity price volatility and geopolitical factors. Analyst consensus is mixed with 34.62% buy ratings, highlighting potential upside if operational execution improves and energy markets stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →
